expected to survive. The responsibility of the physician, having made the diagnosis, was to make the process of dying comfortable. Slowly progressive weakness, lethargy, nausea, vomiting, and a multitude of other symptoms usually precede the preterminal coma that has led some doctors to suggest that uraemia is a comfortable death. That renal failure is a painless death is often true, but that it is a pleasant way to die is a clinical myth. Advances in the replacement of kidney function now provide doctors with alternatives to observing a progressive deterioration. Advances in the management of dying patients ought to have helped those who do not receive treatment, whether because this is not available or because they are not "suitable." Yet the absence of pain as a symptom often seems to make doctors reluctant to give the drugs which help relieve the distress of dying. More thought should be given to making uraemia as a mode of death more acceptable when facilities or clinical circumstances rule out renal replacement.
In 1982 a patient in renal failure is, however, often given treatment, with survival the expected outcome. The prognosis is now better than in many common serious conditions (figure) . As a result of progress in dialysis and in renal transplantation a young patient with renal failure and no complicating features has a better than 90%/0 chance of living 10 years and more.' In most groups of patients accepted for treatment by these methods survival over five years exceeds 50°,,. Even in patients aged over 55 European statistics suggest that with treatment the prospects of survival may not be very different from those for slightly younger patients.1 Such an optimistic assessment is not, however, true of the whole range of older patients, which include many marginally less suitable who are not selected for treatment and so do not enter the analyses. If more such patients were accepted into treatment programmes mortality from non-renal causes would increase. Nevertheless, the trend is for more patients to survive for more years, and this should continue as experience in old and new techniques increases and there is better selection of the right patient for the right treatment. Immunosuppressive treatment, even with conventional agents like prednisolone and azathioprine, may never be raised above 20 mg prednisolone daily with 100 mg of azathioprine. 20 Discharge from hospital at eight days is not unusual in many units, and-after a few weeks of very frequent outpatient supervision this can decrease to a hospital visit every three months.
The merits of such management with the results described are obvious both in human and in economic terms. The money spent may be comparable to that for many major surgical procedures, and less than for some. This description of the course of a patient receiving a renal transplant still applies only to some patients, but the proportion is close to being the majority with a living related donor and is not small with cadaveric donors. The progressive improvements in results, especially when associated with very low dose regimens of immunosuppressives, make it possible to offer most recipients a relatively uneventful and therefore inexpensive procedure. 20 21 With recently introduced drugs such as cyclosporin A, and more still on the horizon, results may in time be found to be even better and more easily achieved. Transplantation may end in failure and a return to dialysis, but success in some hands is now around 800/0 with at least three years of satisfactory kidney function.20 If these results could be achieved nation wide the logistic problems of the supply of donors and of overstressed dialysis facilities would be greatly eased. The reasons for the good results and for the higher failure rate in some series are being sought diligently but without any agreement on the answers. Promising clinical developments such as the use of fine needle aspiration cytology for diagnosing rejection and other techniques that are ready for more clinical trial, need support at the expense, if necessary, of some of the basic research into immunological mechanisms and tissue typing. Publications show a heavy numerical bias to basic research with less contribution made recently to improving mortality and morbidity statistics in renal transplantation.
The problems ofdonor supply and demand have been repeatedly discussed. It has become my view that, excluding severe but temporary setbacks (such as were caused by the Panorama programme),22 the problem can be greatly eased by adequate effort in local organisation and education. The Nottingham and Leicester teams have made a major impact on kidney retrieval rates by appointing full-time supernumerary surgical registrars with responsibility for providing an information, education, and retrieval service. Other units have appointed nurses or lay persons as co-ordinators. There may still be limitations owing to the number of potential donors in a community unless policy changes, or has changed, in the proportion of patients almost certain to die who are given ventilation. The attitude to artificial ventilation in patients with head injuries and cerebrovascular accident at the time of presentation has an important influence on the number of patients considered formally using the criteria for brain death. A reluctance to initiate ventilation, often because of restricted facilities or an irrational feeling that severely brain-damaged survivors will result, may be having a much greater influence on the logistics of the treatment of renal failure than many topics that have been more widely discussed.
Route to solving the problem of too many patients for too fezw facilities
The number of patients in renal failure treated is related to the nation's gross national product.22 Some 
